Low viral load treat it or tolerate it? Hauke Walter Erlangen - PowerPoint PPT Presentation

Oct 01, 2023 •378 likes •455 views

Low viral load treat it or tolerate it? Hauke Walter Erlangen News from HIV-GRADE Algorithms for NRTI, NNRTI, PI, IN without relevant changes Combination tool for NRTIs under investigation Decreasing Role of NRTIs

Low viral load – treat it or tolerate it? Hauke Walter Erlangen
News from HIV-GRADE • Algorithms for NRTI, NNRTI, PI, IN without relevant changes • Combination tool for NRTIs under investigation – Decreasing Role of NRTIs – Implementation of other drug classes in progress • HIV-2 resistance tool developed – Clinical validation in progress (R. Camacho, J. Eberle) • Implementation of HIV-GRADE in CHAIN
Studies • Comparison of coreceptor tropism testing performed form plasma RNA and proviral DNA – First results presented in Paphos – Final results will be presented at DÖAK and International HIV and Hepatitis WS 2011 • Subtyping and coreceptor tropism determination by g2p
Plans • HCV resistance prediction tool • Extension of HIV-GRADE database – At the moment used for storing V3-loop sequence data for HIV-GRADE studies – Open database system planned for optional storing and retrieving anonymous sequence data with every interpretation performed by the HIV-GRADE tools
Project: Influence of low viral load on resistance detection • Observed for pts with 20<VL<200 – A: Crossectional retrospective design – B: Longitudinal design • Aims: – At which viral load resistance testing is meaningful ? • Can clinically relevant resistance be detected ? • Role of BL resistance (new mutation vs any mutation relevant to acutsl ART) • How relevant are VL dynamics (at first confirmed detectable VL vs. at any time with detctable VL) ?
Conclusion • Low VL is the main observation during failure • Currently <50 is the cut-off supported by experience • More data is needed to investigate which VL level may be the best
members Christian Noah Rolf Kaiser 69500 HIV-pos. Lab Lademannbogen Univ Cologne Hamburg ~20% female Patrick Braun 2700 Infections/year Harm Müller Robert Ehret Lab Fenner 700 deaths/year Lab Dr. Knechten Hamburg <2% of newborns HIV-pos Aachen Claudia Kücherer Martin Däumer Berlin Lab Dr. Thiele Kaiserslautern Martin Obermeier Thomas Berg Alexander Thielen Lab Dr. Berg MPI Informatik Berlin Martin Stürmer Hauke Walter Univ. Frankfurt Klaus Korn Univ Erlangen Eva Wolf Josef Eberle Lab Jäger Ref.: RKI Univ Munich Munich

Recommend

Hauke Walter Viral fitness Terminological problems What is viral fitness? The virus adapts

Hauke Walter Viral fitness Terminological problems What is viral fitness? The virus adapts due to selective pressure. Therefore the most fit virus is always the majority, because it has the biggest advantage according to the actual

479 views • 9 slides

Most recent update: 1/2009 Hauke Walter Erlangen members Thomas Berg Martin Obermeier Harm

Most recent update: 1/2009 Hauke Walter Erlangen members Thomas Berg Martin Obermeier Harm Mller Labor Berg Berlin Labor Fenner Hamburg Claudia Kcherer Rolf Kaiser RKI Berlin Uni Kln Hauke Walter Patrick Braun Klaus Korn Robert

155 views • 11 slides

HIV-1 subtype kindergarden Hauke Walter Arevir 2015 HIV-1 subtype distribution Source: Is HIV-1

HIV-1 subtype kindergarden Hauke Walter Arevir 2015 HIV-1 subtype distribution Source: Is HIV-1 evolving to a less virulent form in humans? Kevin K. Arin, Guido Vanham and Eric J. Arts Nature Reviews Microbiology 5, 141-151 (February 2007)

310 views • 20 slides

HCV Viral Load Determination and Therapeutic Consequences? Christoph Jochum Clinic for

HCV Viral Load Determination and Therapeutic Consequences? Christoph Jochum Clinic for Gastroenterology & Hepatology University Hospital Essen What Can HCV viral load possibly tell a physican? When do I need to initiate therapy? How do I

340 views • 30 slides

Hauke Walter Medizinisches Labor Stendal News ticker Changes in the scoring system Update

Hauke Walter Medizinisches Labor Stendal News ticker Changes in the scoring system Update the algorithms New drugs Other targets: HCV resistance tool is mediated via geno2pheno (like HIV coreceptor) HBV (HBs escape mutation

323 views • 9 slides

HIV Community Viral Load in Florida: Methodology, Feasibility, and Implications Kate Goodin, MPH

HIV Community Viral Load in Florida: Methodology, Feasibility, and Implications Kate Goodin, MPH Senior Epidemiologist FDOH, Bureau of HIV/AIDS Kate_Goodin@doh.state.fl.us Viral Load in Individuals Studies have shown that people with

331 views • 19 slides

Inpatient Viral Infections: Which Ones Should We Think About, Test For, and Treat Management of the

10/26/2015 Inpatient Viral Infections: Which Ones Should We Think About, Test For, and Treat Management of the Hospitalized Patient October 2015 Jennifer Babik, MD, PhD Assistant Clinical Professor Division of Infectious Diseases, UCSF Disclosures

504 views • 36 slides

AGM 13 October 2008 BIOTRON LTD (ASX:BIT) Developing world-class drugs to treat viral

AGM 13 October 2008 BIOTRON LTD (ASX:BIT) Developing world-class drugs to treat viral diseases with unmet medical need & large, expanding markets Specific focus on HIV and Hepatitis C virus (HCV) Beyond HIV & HCV,

409 views • 22 slides

Introduction of point - of - care HIV viral load measurement in Macenta, Forest Region, Guinea -

Introduction of point - of - care HIV viral load measurement in Macenta, Forest Region, Guinea - Conakry, West Africa GO VIRAL Image 2 Location of the study site in Macenta Image 1: typical village in the Forest Region Context The HIV

227 views • 4 slides

Making Viral Load Monitoring Routine within ART programmes Presented by Dr.Henry Sunpath

Making Viral Load Monitoring Routine within ART programmes Presented by Dr.Henry Sunpath MEDICATE AIDS NPC Consultant ETHEKWINI HIVVL&DR PROJECT CAPRISA ACC PROGRAM on behalf of the TEAM Kogie Naidoo, Rochelle Adams, Kevi Naidu, Penny

1.31k views • 59 slides

HIV viral load testing in the era of ART Christian Noah Labor Lademannbogen, Hamburg 1 Life

HIV viral load testing in the era of ART Christian Noah Labor Lademannbogen, Hamburg 1 Life expectancy of patients on ART Data from the UK Collaborative HIV Cohort (UK CHIC) Requirements: Early diagnosis Timely initiation of ART

796 views • 32 slides

Low-level Viremia below 50 cps/mL in treated HIV-infected patients predicts viral load rebound

Low-level Viremia below 50 cps/mL in treated HIV-infected patients predicts viral load rebound above 400 cps/mL independently of adherence levels P Vitiello , T Doyle , C Smith , V Cambiano , A Owen*, A Philips , AM Geretti

811 views • 17 slides

Update: Improved Care Stephanie Engagement and Viral Load Chamberlin 1 Suppression among HIV

Mary Irvine 1 Update: Improved Care Stephanie Engagement and Viral Load Chamberlin 1 Suppression among HIV Care Rebekkah Robbins 1 Coordination Clients with McKaylee Psychosocial Barriers at Robertson 2 Baseline Sarah Kulkarni 2 Denis Nash 2

526 views • 21 slides

AREVIR-GenaFor-Meeting Bonn, 05.05.11 ________________ Comparison of HIV-1 Viral Load samples

AREVIR-GenaFor-Meeting Bonn, 05.05.11 ________________ Comparison of HIV-1 Viral Load samples between Real Time (Abbott) and COBAS TaqMan (Roche) ________________ Gudrun Naeth PZB AACHEN Blondelstr. 9 52062 Aachen Introduction Introduction

422 views • 16 slides

Practical Issues with HIV Practical Issues with HIV Testing, CD4 Count and Viral Testing, CD4

Practical Issues with HIV Practical Issues with HIV Testing, CD4 Count and Viral Testing, CD4 Count and Viral Load testing Load testing 2 ND Phnom Penh Symposium on HIV 2 ND Phnom Penh Symposium on HIV Marie Downer, CDC; Chuop Sokheng, NIPH,

104 views • 8 slides

Low Viral Load Time on failure and number of mutations Resistance After AZT/3TC/ABC Failure: CNA

Low Viral Load Time on failure and number of mutations Resistance After AZT/3TC/ABC Failure: CNA 3005 100 90 M184V + any TAM(s) M184V only or WT Percentage of patients 80 76 75 67 60 60 56 44 40 40 33 25 24 20 10 0 08

664 views • 34 slides

Real-Time Applications Tolerant: can tolerate occasional loss of data. Intolerant: cannot tolerate

Real-Time Applications Tolerant: can tolerate occasional loss of data. Intolerant: cannot tolerate such losses. Delay-adaptive: applications that can adjust their playback point (delay or advance over time). Rate-adaptive: can alter the bit rate

218 views • 21 slides

HIV RESISTENCE/ HIV TROPISM AREV I R 2 0 1 9 S TA D T H OT E L A M R M E RT U R M , K L

HIV RESISTENCE/ HIV TROPISM AREV I R 2 0 1 9 S TA D T H OT E L A M R M E RT U R M , K L N 0 3 . 0 4 . M A I 2 0 1 9 Hauke Walter Dr. Joachim Bch Dr. Stefan Scholten In den RingColonnaden F I NANCI AL DI SCL OSURE

597 views • 43 slides

Viral Hepatitis Surveillance in Tennessee NASTAD Viral Hepatitis TA Meeting November 29, 2017

Viral Hepatitis Surveillance in Tennessee NASTAD Viral Hepatitis TA Meeting November 29, 2017 Lindsey Sizemore, Viral Hepatitis Program Director Turning of The Tides HIV Risk Vulnerability Assessment Webinar (CDC, September 2, 2015)

470 views • 28 slides

Exercises for 8.1.3 1. Give a parse tree with semantic records for the statement Z = 2 + 2. Show

326 Chapter 8 Computer Languages TABLE 4. Semantic record label Address Code Expression translated T6 3 The variable Y. T7 Load 0,A The assignment statement Load 2,B Y = 3 + 2*X. Mult A,B,4 Load 4,A Load 1,B Add A,B,5 Load 5,A

427 views • 8 slides

Viral Shedding Viral Shedding <in hospital> <in hospital> into Patients' ??? ???

ICH WORKSHOP: Viral Shedding Review of experience of shedding data for in vivo gene therapy Teruhide YAMAGUCHI Viral Shedding Viral Shedding <in hospital> <in hospital> into Patients' ??? ??? Blood, Urine, Gene Therapy

342 views • 6 slides

Load Balancing Load Balancing Load balancing: distributing data and/or computations across

Load Balancing Load Balancing Load balancing: distributing data and/or computations across multiple processes to maximize efficiency for a parallel program. Static load-balancing: the algorithm decides a priori how to divide the workload.

444 views • 27 slides

Facilitating VIRAL Train the Trainers Now that you have a better understanding of the VIRAL

Facilitating VIRAL Train the Trainers Now that you have a better understanding of the VIRAL framework, we can begin to explain how you might teach it to entrepreneurs and investors in your own ecosystems. Train the Trainers This short session

551 views • 17 slides

Important Viral Infec,ons Viral Infec,ons a/er Hematopoie,c CMV

2/22/13 Important Viral Infec,ons Viral Infec,ons a/er Hematopoie,c CMV Cell Transplanta,on HHV-6 Adenovirus Michael Boeckh, MD EBV Fred

474 views • 8 slides